Puma Biotechnology Inc   (PBYI)
Other Ticker:  
Price: $3.1900 $-0.01 -0.313%
Day's High: $3.26 Week Perf: 4.59 %
Day's Low: $ 3.16 30 Day Perf: 19.48 %
Volume (M): 259 52 Wk High: $ 5.16
Volume (M$): $ 826 52 Wk Avg: $3.24
Open: $3.20 52 Wk Low: $1.79

 Market Capitalization (Millions $) 150
 Shares Outstanding (Millions) 47
 Employees 460
 Revenues (TTM) (Millions $) 235
 Net Income (TTM) (Millions $) 5
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 13

Puma Biotechnology Inc
Puma Biotechnology Inc. is an American biopharmaceutical company founded in 2010 and headquartered in Los Angeles, California. The company specializes in the development of innovative drugs for the treatment of cancer, with a particular focus on breast cancer, the second most common cancer in women worldwide.

Puma Biotechnology's main product candidate is Neratinib, a small molecule tyrosine kinase inhibitor (TKI) that targets HER2 (human epidermal growth factor receptor 2), a receptor that is overexpressed in approximately 20% of breast cancer patients. HER2 overexpression is associated with more aggressive tumors, higher rates of recurrence, and poorer prognosis.

Neratinib is being developed as an extended adjuvant therapy for patients with HER2-positive early stage breast cancer who have completed standard of care treatment with trastuzumab, another HER2-targeted therapy, and chemotherapy. The extended adjuvant therapy with neratinib is intended to reduce the risk of disease recurrence and improve overall survival.

Puma Biotechnology completed several pivotal clinical trials of neratinib, including the Phase III ExteNET trial, which enrolled over 2,800 patients and demonstrated a statistically significant improvement in disease-free survival compared to placebo. The company has also conducted clinical trials of neratinib in other HER2-positive cancers, including metastatic breast cancer, HER2-mutant solid tumors, and glioblastoma.

In addition to neratinib, Puma Biotechnology has a pipeline of other drug candidates in preclinical and clinical development, including PB272 (neratinib in combination with another TKI), PB357 (a novel kinase inhibitor), and PB891 (an antibody-drug conjugate).

Puma Biotechnology has a global commercialization agreement with Pierre Fabre, a French pharmaceutical company, for the commercialization of neratinib in Europe, Latin America, Africa, and select other countries. The company also has licensing agreements with various academic institutions and biotech companies for the development of its drug candidates.

The company has a market capitalization of approximately $6 billion as of August 2021 and employs approximately 200 people. Puma Biotechnology is publicly traded on the NASDAQ stock exchange under the ticker symbol PBYI.

   Company Address: 10880 Wilshire Boulevard, Suite 2150 Los Angeles 90024 CA
   Company Phone Number: 248-6500   Stock Exchange / Ticker: NASDAQ PBYI
   PBYI is expected to report next financial results on August 03, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Q Biomed Inc

The company has Turned into Profitability at the Major Pharmaceutical Preparations company in the fourth quarter of 2022 earnings season

For the fourth quarter of 2022 earnings season Q Biomed Inc had turn a round to surplus by exhibiting earnings per share of $0.02 per share compare to $-0.08 a year before and earnings per share turned positive from $-0.03 per share from the prior financial reporting period. The revenue went down sharply by -88.053 % to $0.01 million from $0.10 million in the comparable financial reporting period a year before and sequentially Revenue Tumbled by -52.286 % from $0.03 million.

23andme Holding Co

Redemption of Diminishing Returns at ME amid the fourth quarter of 2023 earnings season

23andme Holding Co Posts Mixed Q4 Results, Despite Lower Demand
23andme Holding Co, the popular genetic testing company, has released its latest earnings report for Q4 2023. In a disappointing development for investors, the company's revenue was hit hard by lower demand, leading to a vanishing revenue and higher deficit.
While the earnings report may have been mixed, there was some positive news to report. The company announced that it had been able to decrease its loss per share to $-0.13 per share, which may be seen as an encouraging sign to some investors. However, revenue decreased by -8.137% to $92.38 million, signifying that the company still has some way to go in order to generate more growth.

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc released operating deficit of $-1.54478 million, in the Mar 31 2023 report

As the earnings season for January to March 31, 2023, continues, many corporations have announced their respective results. The pharmaceutical industry, a significant player in the global market, has also been reporting their earnings. One company that has recently released its earnings report is Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc (SHPH), a rising player in the industry, has issued an operating deficit of $-1.54478 million for the first quarter of the 2023 earnings season. While the shareholders anticipate additional revenue sources to evolve in the near future, they are less interested in the corporation's current accomplishment.
It is not surprising that the company realized a net loss of $-0.975 million, which has extended from $-0.078 million in the financial quarter ending March 31, 2022. The shareholders' expectations of additional revenue streams reflect the investors' desire to see solid growth and profitability in the long run.
However, it is essential to understand that the pharmaceutical industry is highly competitive, which means that many significant companies operate in this space. These companies tend to have diversified product portfolios, expansive distribution networks, and significant marketing budgets, which can help secure their market share and profitability.
It is noteworthy that Shuttle Pharmaceuticals Holdings Inc is a rising player in the pharmaceutical industry, which means that the company is still finding its feet in the market. The most crucial measure of the company's growth and profitability in the long run will stem from the successful development, approval, and commercialization of its pipeline products.

Bullfrog Ai Holdings Inc

Bullfrog Ai Holdings Inc reported operating deficit of $-1.190645 million, in the Mar 31 2023 report

Bullfrog AI Holdings Inc: An Overview
Bullfrog AI Holdings Inc is a pharmaceutical company that specializes in creating innovative drugs using artificial intelligence (AI) technology. The company was founded in 2019, with headquarters located in Toronto, Canada. Bullfrog AI Holdings Inc is focused on developing new drugs for diseases that have no known cure. The company's primary aim is to revolutionize the pharmaceutical industry with its cutting-edge technologies and creative solutions.
The company's technological capabilities come from its emphasis on AI, machine learning, and data analytics. Bullfrog AI Holdings Inc uses AI technology to analyze vast amounts of data to identify drug candidates that have a high likelihood of success in clinical trials. This approach enables the company to produce drugs that are more efficient and effective than traditional drugs.

Ocean Biomedical Inc

Between many entities, the OCEA disclosed as well the first quarter of 2023 performance

Ocean Biomedical Inc. is a major pharmaceutical preparations company that specializes in developing, manufacturing, and distributing drugs and medical devices. The company has been in operation for several years and has a strong track record within the industry. However, like many companies in the pharmaceutical sector, Ocean Biomedical operates within a highly competitive market, where constantly evolving regulatory environments, technological advancements, and shifting consumer demands can have a significant impact on the company's performance.
In the first quarter of 2023, Ocean Biomedical Inc. faced significant challenges. The company announced a shortfall of $-67.401 million, which was a significant drop from the $0.043 million net income reported in the same period the previous year. The unexpected adjustment in revenue during the January to March 31 2023 reporting cycle caught shareholders off guard. However, investors had been monitoring Ocean Biomedical's operational shortfall, which stood at $-5.223 million during the same period.


Puma Biotechnology Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071